Clinical Research Directory
Browse clinical research sites, groups, and studies.
Patients With Rectal Cancer: a "Wait-and-see" Approach
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Summary
Patients with histologically proven adenocarcinoma of the rectum will receive pelvic radiotherapy to a dose of 45Gy in 25 fractions with a tumor boost to a dose of 9Gy in 5 fractions (thus total of 54Gy/30Fx to the primary tumor), combined with radio sensitizing chemotherapy. Patients will then be closely monitored, through endoscopy and imaging, for response to treatment and relapse. Salvage oncologic surgery to be offered if there is failure to achieve complete clinical response or in the event of a loco regional relapse.
Official title: Radical External Beam Chemoradiation in Patients With Rectal Cancer: a "Wait-and-see" Approach
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2015-03
Completion Date
2026-01
Last Updated
2025-05-15
Healthy Volunteers
No
Conditions
Interventions
Radical external beam radiotherapy
pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
Locations (2)
McGill University Health Center-Cedars Cancer Centre
Montreal, Quebec, Canada
McGill University Health Centre- Cedars Cancer Centre
Montreal, Quebec, Canada